Stealth BioTherapeutics (MITO) Now Covered by Analysts at Evercore ISI

Share on StockTwits

Evercore ISI started coverage on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $35.00 target price on the stock.

Separately, BMO Capital Markets started coverage on shares of Stealth BioTherapeutics in a research report on Tuesday. They set an outperform rating and a $29.00 price target on the stock.

Shares of MITO stock opened at $14.72 on Tuesday. Stealth BioTherapeutics has a twelve month low of $11.11 and a twelve month high of $20.99.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

See Also: Gap Up Stocks

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Increases Fidelity National Information Servcs  Price Target to $140.00
Wedbush Increases Fidelity National Information Servcs Price Target to $140.00
ValuEngine Upgrades Lannett  to Hold
ValuEngine Upgrades Lannett to Hold
International Flavors & Fragrances  & Methanex  Head to Head Review
International Flavors & Fragrances & Methanex Head to Head Review
Analyzing Clearway Energy Inc Class C  & Entergy
Analyzing Clearway Energy Inc Class C & Entergy
Darden Restaurants  Given a $130.00 Price Target by Bank of America Analysts
Darden Restaurants Given a $130.00 Price Target by Bank of America Analysts
Commercial Metals  Lifted to Outperform at Macquarie
Commercial Metals Lifted to Outperform at Macquarie


© 2006-2019 Ticker Report